The Regulatory Bottleneck: Why Sunscreen Innovation Stalled for Two Decades

The FDA recently approved BEMT (Bemotrizinol), the first new sunscreen ingredient in over 20 years. This approval highlights a mismatch between public health goals and drug classification. By treating sunscreens as over-the-counter (OTC) drugs instead of cosmetics, the U.S. requires manufacturers to follow a high-cost, animal-testing-heavy approval process that discourages innovation. The result is that Americans often use older, less efficient formulations while the rest of the world adopts safer, more effective alternatives. For industry observers and consumers, this shows how "safety-first" regulation can delay the adoption of superior technology, putting domestic products at a disadvantage and creating a confusing market for users.

The High Cost of the "Drug" Label

The stagnation of sunscreen innovation stems from a classification error. While most of the world regulates sunscreen as a cosmetic, the U.S. categorizes it as an OTC drug, placing it in the same regulatory category as aspirin. As health journalist Michael Scaturro notes, this classification requires a rigorous, expensive, and often redundant testing process.

"I think the main reason is that it's expensive to bring a new drug through the FDA because in the United States, sunscreen chemicals are considered over-the-counter drugs... And those are things that have to go through traditionally an animal testing process."

-- Michael Scaturro

This creates a barrier to entry that favors the status quo. When it costs $18 million to bring a single chemical through the FDA, only large companies can afford to innovate. This system incentivizes the "safe" choice of maintaining the current, aging list of ingredients over the "better" choice of adopting globally vetted, modern filters like BEMT.

Efficiency vs. The "White Cast" Problem

From a chemical perspective, the U.S. market is stuck in a loop of inefficiency. Because current U.S.-approved organic filters are limited, formulators must combine multiple chemicals to achieve broad-spectrum protection. This consumes the "real estate" of a sunscreen formula, often requiring the addition of inorganic minerals like zinc oxide or titanium dioxide to fill the gaps.

As chemistry PhD candidate AJ Ade explains, these minerals are effective but come with a significant aesthetic and functional downside: the "white cast." These minerals scatter visible light, creating the chalky residue that discourages many users from consistent application. BEMT solves this by offering broad-spectrum UVA and UVB absorption in a single, stable molecule, allowing for more transparent, efficient formulations.

"Typically you have to combine several different UV filters and sunscreens to get a broad spectrum claim, whereas with BEMT you can do so a little bit more efficiently without taking up so much of the sunscreen's real estate."

-- AJ Ade

The "Gray Area" and the Erosion of Trust

The regulatory system’s cautious approach has created a paradoxical "gray area." In 2019, the FDA reclassified several long-standing sunscreen ingredients as "not GRASE" (Generally Recognized as Safe and Effective) after detecting trace amounts in the bloodstream. While the FDA clarified this did not mean the ingredients were unsafe, only that more data was required, public perception shifted toward skepticism.

This has resulted in a fragmented market. In Europe, companies market products as "free of" specific chemicals that are still widely used in the U.S. because they exist in this regulatory limbo. The system has created an environment where domestic consumers are exposed to older, less-vetted chemicals, while the global market has moved on. The irony is that BEMT, which is now the most heavily vetted ingredient globally, was held to the same slow, expensive animal-testing standards as unknown substances, despite having years of real-world safety data from other countries.

Key Action Items

• Monitor Ingredient Labels (Immediate): Start looking for BEMT (Bemotrizinol) in product ingredient lists starting late October. It represents a significant upgrade in broad-spectrum efficiency over current U.S. standards.
• Shift Evaluation Metrics (Immediate): Stop equating "FDA-approved" with "the most advanced option." In the case of sunscreens, the regulatory lag means domestic products have historically trailed behind international standards by decades.
• Advocate for Regulatory Modernization (12-18 months): Support legislative efforts that nudge the FDA toward accepting non-animal, alternative toxicological data. The current reliance on outdated testing models is the primary bottleneck for new, safer chemistry.
• Prioritize Broad-Spectrum Efficiency (Ongoing): When choosing sunscreens, look for formulations that achieve high SPF and UVA protection without relying on heavy mineral aggregates. This reduces the "white cast" and encourages more frequent, consistent usage, which is the most important factor in skin cancer prevention.
• Navigate the "Gray Area" (Ongoing): Be aware that many U.S. sunscreens currently on shelves contain ingredients that the FDA has flagged as lacking sufficient data. While not explicitly "unsafe," these ingredients are being phased out globally; prioritize products with newer, more transparent chemical profiles as they become available.